Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.

[1]  Min Song,et al.  Pharmacokinetics of HZ08 in rats by liquid chromatography-tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  R. Findling,et al.  A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. , 2007, Journal of child and adolescent psychopharmacology.

[3]  B. Ott,et al.  Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease , 2007, Journal of Neurology.

[4]  Roy W Jones,et al.  Safety and tolerability of once‐daily versus twice‐daily memantine: a randomised, double‐blind study in moderate to severe Alzheimer's disease , 2007, International journal of geriatric psychiatry.

[5]  M. Ryan,et al.  A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease , 2007, Expert opinion on drug metabolism & toxicology.

[6]  Y. Higashi,et al.  Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent. , 2006, Biomedical chromatography : BMC.

[7]  Jon W. Johnson,et al.  Mechanism of action of memantine. , 2006, Current opinion in pharmacology.

[8]  A. Periclou,et al.  Pharmacokinetic study of memantine in healthy and renally impaired subjects , 2006, Clinical pharmacology and therapeutics.

[9]  Abraham Weizman,et al.  Memantine for treatment-resistant OCD. , 2005, The American journal of psychiatry.

[10]  N. Rao,et al.  Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. , 2005, Clinical therapeutics.

[11]  Tsai-Hui Duh,et al.  Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation. , 2005, Journal of chromatography. A.

[12]  G. C. Palmer.  Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. , 2001, Current drug targets.

[13]  M. Zhang,et al.  Sensitive and selective liquid chromatographic assay of memantine in plasma with fluorescence detection after pre-column derivatization. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[14]  G. Houin,et al.  Clinical Pharmacokinetics of Acamprosate , 1998, Clinical pharmacokinetics.

[15]  M. Tod,et al.  Clinical Pharmacokinetics of Diacerein , 1998, Clinical pharmacokinetics.

[16]  P. Fusar-Poli,et al.  Memantine as a neuroprotective agent in early phases of psychosis. , 2007, Medical hypotheses.

[17]  J. Kornhuber,et al.  Memantine Pharmacotherapy , 2007, Clinical pharmacokinetics.